About Index Trending news
Analyze
Pricing
Blueprint Medicines

Blueprint Medicines

Blueprint Medicines

Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO debt
$125,000,000
Venture capital (Series C)
$50,000,000
Employees

Team size

10+
Locations
HQ
$125,000,000 Post-IPO debt
Twitter

Biotech Day on Twitter

Xconomy

Blueprint, Roche Ink Milestone Deal for Cancer Immunotherapy

Health Science